Fadogia Agrestis
Best-in-class: Fadogia Agrestis
A West-African shrub extract popularized (with Tongkat Ali) for boosting testosterone by acting like luteinizing hormone (LH) on the testes.
Fadogia Agrestis quick facts
| Suggested dose | Commonly 300–600 mg cycled (e.g., 8–12 weeks on, then off) — but human data is lacking. |
| How often | Cycled - 8-12 weeks on, then off |
| Who it's for | Experienced users experimenting with natural testosterone support. |
The part that gets repeated far less often than the testosterone claim: the same rodent literature reported testicular toxicity and reduced sperm parameters at higher doses. Taking an unstudied compound for hormonal effect while the only available toxicology points at the organ you are targeting deserves more caution than it usually gets. Genuinely interesting mechanism, genuinely absent human evidence.
How Fadogia Agrestis actually works
Raised testosterone substantially in rat studies, apparently by acting directly at the Leydig cell to increase steroidogenesis. That single rodent finding is the entire basis of its popularity — there is no human pharmacokinetic, efficacy or safety data of any kind.
Where to get Fadogia Agrestis
Find Fadogia Agrestis on iHerb →The evidence for Fadogia Agrestis
Graded by what exists behind each claim.
✅ Clinically validated
- Evidence is almost entirely RODENT — animal studies show raised testosterone and libido.
- No quality human trials yet; human dosing and safety are extrapolated.
📊 Correlative data
- Popular anecdotal 'stacked with Tongkat' reports of higher drive and testosterone.
🧪 Theoretical / extrapolated benefits
- The LH-mimetic mechanism is plausible, but this is genuinely experimental — animal data raised organ-toxicity questions at high doses.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Fadogia Agrestis actually does
The honest mechanism section for Fadogia agrestis has to start by saying what is not known, because the list is longer than the list of what is. The plant is a West African shrub of the Rubiaceae. Its isolated constituents include monoterpene glycosides characterized from the stem Anero 2008, and phenolic compounds have been quantified in both plant material and finished dietary supplements by liquid chromatography with mass spectrometry Avula 2019. No single constituent has been shown to carry the androgenic effect.
The proposed mechanism is luteinizing-hormone mimicry, and it is an inference from an outcome rather than a demonstrated binding. The original rodent study reported raised serum testosterone after aqueous stem extract Yakubu 2005, and the interpretation that this reflects action at the Leydig cell rather than elsewhere in the axis has not been tested with a receptor assay or with gonadotropin measurement in people.
What the follow-up rodent work actually measured was the testis. Oral administration of the aqueous extract was examined against testicular function indices in male rats Yakubu 2008, and a further study characterized the mode of cellular toxicity of the same extract in rat liver and kidney Yakubu 2009. Those are the two papers that define what is known about the safety of this plant, and both are rodent papers.
The clock here is the study duration, and it is short. The rodent work is measured in days and weeks of daily dosing Yakubu 2008 Yakubu 2009. No human pharmacokinetics exist, so there is no half-life, no accumulation estimate and no basis on which any human dosing interval has ever been chosen.
Cell, rodent, human — and where it stops
The cell-to-rodent-to-human chain does not break on this page. It stops, because the human step was never taken.
What has been measured, and in what. Aphrodisiac potential of the aqueous stem extract in male albino rats Yakubu 2005. Testicular function indices after oral administration in male rats Yakubu 2008. Cellular toxicity in rat liver and kidney Yakubu 2009. Chemical characterization of constituents Anero 2008 and quantification of phenolics in supplements Avula 2019. That is the literature. There is no randomized human trial, no dose-ranging study and no safety follow-up in people.
The specific obstacle is that a rodent testosterone rise is a weak predictor in this exact category. The comparison case is instructive: Tribulus terrestris raised androgens in animal work and then failed to influence androgen production in young men when it was finally tested Neychev 2005. The rodent-to-human transfer for botanical androgen claims has a poor track record and this compound has not yet been given the chance to fail it.
The second obstacle is that the dose came from nowhere. The 300 to 600 mg figure in circulation has no human study behind it and no allometric derivation published from the rodent doses Yakubu 2005. It is a number that propagated through media rather than through a protocol.
What would close the gap. A dose-ranging human study with luteinizing hormone, follicle-stimulating hormone, total testosterone and a liver panel, run against a characterized extract of declared constituent content Avula 2019. Until that exists, everything on a label for this ingredient is extrapolation.
Fadogia Agrestis — which form, and does it matter
The form question is unusually stark: nobody has agreed what the active is, so nobody can standardize to it. Products declare milligrams of stem extract and sometimes a ratio. Quantification work using liquid chromatography with photodiode array and mass spectrometry measured phenolic compounds in both raw material and finished dietary supplements Avula 2019, which is the analytical basis for saying that commercial products differ from each other.
The isolated chemistry that does exist is not what labels reference. Monoterpene glycosides have been isolated and characterized from this species Anero 2008. No product standardizes to them, and no study links them to the androgenic outcome.
Botanical identity is a live question across this trade. Independent testing of sports supplements has measured the presence and quantity of botanical ingredients against what the labels claimed and found substantial disagreement Cohen 2023. A plant with no assay and high demand is the profile where that disagreement is most likely.
Nothing here asserts the contents of any bottle. supplements_data.BLENDS holds no filed panel for a Fadogia product, and this page makes no claim about what any specific product contains.
What would have to be true, and how you would know it was not
1. The gonadotropin prediction, which distinguishes the proposed mechanism from the alternatives. Luteinizing hormone, follicle-stimulating hormone and total testosterone at baseline and 8 weeks. Predict that if the luteinizing-hormone-mimetic account is right, testosterone rises while measured luteinizing hormone falls under negative feedback. A rise in both would point somewhere else entirely Yakubu 2005.
2. The liver and kidney prediction, and it is the reason to measure at all. Alanine aminotransferase, aspartate aminotransferase, bilirubin, creatinine and estimated glomerular filtration rate at baseline, 4 weeks and 8 weeks. The rodent toxicity work is specifically about liver and kidney Yakubu 2009, so those are the organs to watch rather than a general wellness panel.
3. The testicular prediction, and it is the one that would end this ingredient. Predict that if the rat testicular findings Yakubu 2008 transfer, they would show up first as a falling follicle-stimulating hormone response or a falling sperm concentration on a semen analysis, not as a symptom. Nobody has looked.
4. The null prediction, drawn from the closest precedent. Predict no change in total testosterone in young men with normal baseline androgens, because that is what happened when the analogous botanical was finally tested in exactly that population Neychev 2005.
5. The content prediction. Have two products assayed. Predict they differ, because independent testing of botanical ingredients in sports supplements found declared and measured quantities disagreeing Cohen 2023 Avula 2019.
What nobody has tested yet
Nobody has run a human trial of any kind. Not a pharmacokinetic study, not a dose-ranging study, not a randomized endpoint trial. The entire literature is preclinical Yakubu 2005 Yakubu 2008 Yakubu 2009.
Nobody knows what the active constituent is. Monoterpene glycosides are characterized Anero 2008 and phenolics are quantified Avula 2019, and neither has been tied to the androgenic outcome.
Nobody has established a no-observed-adverse-effect level. The rodent toxicity work describes a mode of cellular injury Yakubu 2009 without giving a human-relevant safety margin.
And nobody has tested the cycling advice. Eight to twelve weeks on and then off is repeated everywhere and rests on no study of either the on period or the off period.
Fadogia Agrestis — its own safety story, not its category's
This is the entry in this batch with the widest gap between how confidently it is sold and how little is known, and the gap belongs in the safety section rather than in a footnote. The mode of cellular toxicity of the aqueous stem extract in rat liver and kidney has been characterized Yakubu 2009, and testicular function indices were the endpoint of a separate rodent study Yakubu 2008. There is no human safety data at all: no trials, no dosing studies, no long-term follow-up.
The popular dose has no derivation. The 300 to 600 mg range in circulation was not calculated from the rodent doses Yakubu 2005 and was not established in people. Anyone taking it is using a number with no provenance.
If somebody is going to use it anyway, the monitoring is the part that is actionable. A baseline liver and kidney panel and a hormone panel including luteinizing hormone and follicle-stimulating hormone, repeated during use, is what the rodent findings point at Yakubu 2009 Yakubu 2008. Stating that plainly is more useful than leaving the page blank and letting the dose be found somewhere with less honesty.
Product identity is part of the risk. Independent assays of botanical ingredients in sports supplements have found declared and measured content disagreeing Cohen 2023, and a plant with no accepted marker compound Avula 2019 cannot be verified by a certificate that does not name one. Not for use in pregnancy, not for anyone with liver or kidney disease, and not for anyone being investigated for a fertility problem. Nothing here is medical advice or a diagnosis, and none of these statements has been evaluated by the Food and Drug Administration.
Sources read for this page
- Yakubu MT. Aphrodisiac potentials of the aqueous extract of Fadogia agrestis (Schweinf. Ex Hiern) stem in male albino rats. Asian J Androl 2005 · PMID 16281088
- Yakubu MT. Effects of oral administration of aqueous extract of Fadogia agrestis (Schweinf. Ex Hiern) stem on some testicular function indices of male rats. J Ethnopharmacol 2008 · PMID 18023305
- Yakubu MT. Mode of cellular toxicity of aqueous extract of Fadogia agrestis (Schweinf. Ex Hiern) stem in male rat liver and kidney. Hum Exp Toxicol 2009 · PMID 19755438
- Avula B. Quantification of Phenolic Compounds from Fadogia agrestis and Dietary Supplements using UHPLC-PDA-MS. Planta Med 2019 · PMID 30170324
- Anero R. Monoterpene glycosides isolated from Fadogia agrestis. Phytochemistry 2008 · PMID 17988698
- Neychev VK. The aphrodisiac herb Tribulus terrestris does not influence the androgen production in young men. J Ethnopharmacol 2005 · PMID 15994038
- Cohen PA. Presence and Quantity of Botanical Ingredients With Purported Performance-Enhancing Properties in Sports Supplements. JAMA Netw Open 2023 · PMID 37459101
How you would know if it worked
There are no human trials. That is not a reason to skip the blood work, it is the reason to insist on it: with no trial to inherit, a draw in you is the only evidence this does anything in you. Total and free testosterone before, and again after eight weeks at the same dose, is the whole experiment. LH and FSH are the more interesting pair, because the marketed mechanism is that it acts on the testes the way luteinizing hormone does — and if that is true, testosterone rises while LH settles back. The pattern nobody markets is the one the rodent toxicity findings raise: LH and FSH climbing while testosterone stays flat or drops is what a testis being pushed harder and answering less looks like. That is a reason to stop and see a doctor, not to raise the dose.
- Total Testosterone Retest: 6–8 weeks after any protocol change; every 3–6 months on TRT.
- Free Testosterone Retest: With every total T retest — they must be interpreted together.
- LH & FSH Retest: Baseline before TRT; when investigating low T; when planning fertility.
The cheapest panel carrying Free Testosterone and at least one other of these is Prolactin Came Back High, at $215 — the panel is named for a different question, and the marker is the same marker. That is the whole cost of finding out.
Draw before you start, not after. A result with nothing to compare it to answers nothing.
Fadogia Agrestis — safety & side effects
- The one in this category we would flag hardest. Rodent studies at high doses have shown testicular toxicity, and there is no human safety data at all — no trials, no dosing studies, no long-term follow-up.
- The popular dosing came from a podcast rather than a protocol. Nobody has established a human dose, a ceiling, or what chronic use does.
- If you use it, cycle it, keep the dose conservative, and run a hormone panel including LH and FSH. We would rather say that plainly than leave it off the page and have you find the dose somewhere with less honesty.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Best-in-class brand pick
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Fadogia Agrestis in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Fadogia Agrestis
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Total Testosterone | The claim, and the human evidence for it is very thin |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney. Animal work shows organ toxicity at higher doses |
| LH & FSH | Whether anything is happening upstream at all |
The “Low T? Rule Out the Reversible Causes First” panel covers these in one order — 11 markers, $211.50 with the discount applied.
Check results you already have → · All 103 markers A–Z
Fadogia Agrestis — frequently asked questions
What is Fadogia Agrestis?
A West-African shrub extract popularized (with Tongkat Ali) for boosting testosterone by acting like luteinizing hormone (LH) on the testes.
What is the suggested dose of Fadogia Agrestis?
Commonly 300–600 mg cycled (e.g., 8–12 weeks on, then off) — but human data is lacking. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Fadogia Agrestis dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Fadogia Agrestis?
Coach Cam sources Fadogia Agrestis from vetted, top-rated brands on iHerb — use the buy link on this page.
What Fadogia Agrestis is used for
Fadogia Agrestis appears under 2 goals in the goal router.
Related Hormonal & Wellness supplements
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.